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Captopril potentiates the vasodepressor action of
Met-enkephalin in the anaesthetized rat
R. Di Nicolantonio, J.S. Hutchinson, Y. Takata&M. Veroni
University of Melbourne, Department of Medicine, Austin Hospital, Heidelberg, Victoria, 3084, Australia
1 The transient vasodepressor action of Met-enkephalin (10-80Aggkg-1, i.v.) in anaesthetized rats
was significantly potentiated by the angiotensin-converting enzyme inhibitor, captopril (2 mg kg-1,
i.v.); at this dose, it failed to modify the transient vasodepressor action of the non-specific
vasodilator, nitroprusside (2.5, 5.0, 10 g kg-l, i.v.).
2 Captopril (2 mg kg-1, i.v.) caused a slow, progressive fall in the blood pressure of anaesthetized
spontaneously hypertensive (SH) rats when compared to vehicle-treated controls. Pretreatment
with naloxone (1.5 mg kg-1, i.v.) 30 min earlier failed to alter significantly the hypotensive action of
captopril in anaesthetized SH rats.
3 It was concluded that although captopril potentiated the vasodepressor action of Met-
enkephalin in anaesthetized normotensive rats, potentiation of endogenous opioids does not appear
to be involved in the hypotensive action of captopril in anaesthetized SH rats.
Introduction
Angiotensin-converting enzyme (ACE) is a
dipeptidyl-dipeptidase capable of cleaving the de-
capeptide angiotensin I to produce the potent, pres-
sor octapeptide angiotensin II (Soffer, 1976). Cap-
topril is an orally active and relatively specific in-
hibitor of ACE, as well as an effective antihyperten-
sive agent in man and other animals (Heel, Brogden,
Speight & Avery, 1980; Cushman, Cheung, Sabo &
Ondetti, 1981).
While the hypotensive action of captopril is be-
lieved to be secondary to the blockade of ACE
(Antonaccio, Rubin & Horovitz, 1980), the precise
mechanism is unclear. Captopril has been shown to
lower blood pressure of spontaneously hypertensive
(SH) rats by a mechanism that is apparently indepen-
dent of both the renal and vascular wall renin-
angiotensin system (Hutchinson & Mendelsohn,
1980). The finding that both bradykinin (Dorer,
Kahn, Lentz, Levine & Skeggs, 1974) and enkepha-
lin (Erdos, Johnson & Boyden, 1978) are substrates
for ACE raises the possibility that potentiation of
either of these peptides by captopril could be in-
volved in the acute hypotensive action of captopril in
the anaesthetized SH rat. However, despite the find-
ing that captopril increases the level of circulating
kinins in experimental animals (McCaa, Hall &
McCaa, 1978; Matthews & Johnston, 1979),
bradykinin is not believed to play a major role in the
hypotensive action of captopril in animals (see review
Antonaccio et al., 1980) or man (Millar & Johnston,
1979). The role of endogenous opioids in the
hypotensive action of captopril has not yet been
examined; however, the finding that captopril poten-
tiates morphine-induced respiratory depression
(Oktay, Onur, Mustafa & Turker, 1981) and
analgesia (Ercan, Ilhan & Turker, 1980) suggests
that ACE is involved in the metabolism of endogen-
ous opiates and that captopril treatment may result in
the accumulation of endogenous opioids.
Intravenous administration of the opioid peptide,
methionine-enkephalin (Met-enkephalin) to the
anaesthetized cat (Moore & Dowling, 1980) and rat
(Wei, Lee & Chang, 1980) results in a rapid, trans-
ient fall in blood pressure. Given that the degradation
of systemic enkephalin is believed to be by the action
of a dipeptidyl dipeptidase associated with vascular
endothelial tissue (Erdos et al., 1978; Benuck &
Marks, 1979), we have examined whether or not
captopril can modify the acute vasodepressor action
of exogenous Met-enkephalin in the anaesthetized
rat. Furthermore, we have investigated, with the use
of the opiate receptor antagonist, naloxone, whether
or not potentiation of endogenous opioids is involved
in the hypotensive action of captopril in the anaes-
thetized SH rat.
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Methods
Anaesthetized rat bioassay
Male Wistar Kyoto rats (250-350 g) were anaesthet-
ized with Inactin (sodium salt of 5-ethyl-5-(11-
methylpropyl)-2-thiobarbituric acid) (100mg kg-1,
i.p.), an anaesthetic without any hypotensive action
(Munoz-Ramirez, Khosla, Bumpus & Khairallah,
1978). Tracheostomy was performed and cannulae
placed in the left jugular vein for drug injections and
the left common carotid for the continuous recording
of mean blood pressure on a Grass polygraph (Model
7C) via p23 dB Statham pressure transducers. Ani-
mals respired spontaneously; a moist oxygen supple-
ment was supplied and body temperature was main-
tained at 36.5°C with an electric blanket.
Drug interactions
Experiment 1: one hour after surgery, intravenous
(i.v.) bolus injections of Met-enkephalin (Bachem)
were given (10, 20, 40, and 80 tig kg-I each in 0.1 ml)
in a randomized manner at 10 min intervals. Each
animal then received either captopril (2 mg kg- 1, i.v.)
or saline (0.1 ml, i.v.) and the doses of Met-
enkephalin were repeated. In a further group of rats,
the effect of naloxone (1.5 mgkg 1, i.v.) on the re-
sponse to a 40 jig kg-' dose of Met-enkephalin was
studied over a 3 h period.
Experiment 2: The protocol of Experiment 1 was
followed except that nitroprusside (Roche) was given
in 3 doses (2.5, 5 and lOiggkg-1) instead of the 4
doses of Met-enkephalin.
Experiment 3: spontaneously hypertensive (SH)
rats of the Okamoto strain (250-300g) were pre-
pared as above and 1 h after surgery they received
either naloxone (1.5 mg kg-1, i.v.) or vehicle (0.1 ml
of 0.9% saline, i.v.). After a further 30 min each rat
received a bolus injection of captopril (2 mg kg-1,
i.v.). Blood pressure was monitored continuously
until 3 h after captopril had been given.
Two way analysis of variance (Armitage, 1977) was
used to test for the significance of differences in
responses to Met-enkephalin during the treatment
periods and also to assess the effect of naloxone on
the hypotensive action of captopril in SHR. Student's
paired ttest was also used to assess the significance of
differences in responses to Met-enkephalin during
the treatment periods.
Results
Experiment 1: intravenous Met-enkephalin caused a
dose-dependent, transient fall in blood pressure in
anaesthetized rats. Expressed as a percentage fall in
blood pressure, the response ranged from 8% at its
lowest dose of 10ILgkg-I to 26% at 80 jgkg-'. The
vasodepressor response to each dose of Met-
enkephalin following captopril was significantly gre-
ater than the corresponding pretreatment value
(F1,32 =14.2, P<0.05), the results being shown in
Table 1.
However, the vasodepressor responses to in-
travenous Met-enkephalin following the saline injec-
tion were not significantly different from the corres-
ponding controls (F1,24= 1.1, P> 0.05) (Table 1).
Naloxone antagonized Met-enkephalin, the re-
sponses being about 80% reduced 3 h after naloxone
was given.
Experiment 2: captopril in an identical regime to
Experiment 1 failed to modify significantly the dose-
dependent, transient hypotensive effect of nitroprus-
side in the anaesthetized rat whether the values were
expressed as absolute or as percentage falls in blood
pressure (F1,18 = 0.1, P> 0.05). The fall in blood
pressure ranged from 25 mmHg at 2.5 fg kg1 to
50 mmHg at 10 tig kg 1 nitroprusside.
Experiment 3: captopril (2mg kg-1, i.v.) caused a
gradually developing fall in blood pressure, over 3 h,
in anaesthetized SH rats (n = 8) pretreated with vehi-
Table 1 Effects of captopril, naloxone or saline on vasodepressor responses to intravenous methionine-



















(1.5 mg kg-1, i.v.)
18*t
Results are expressed as a % of controls with 5- 7 rats in each experiment.
*P< 0.01 when compared to control values as assessed by paired ttest.
tResponses measured 3 h after naloxone treatment.
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cle (190 ± 3 to 172 ± 3 mmHg, P< 0.005) which was
not significantly different (F1,16 =0.1, P>0.05)
from that in SH rats pretreated with 1.5mgkg1
naloxone (193 ± 4 to 171 ± 6 mmHg).
Discussion
In the present study captopril significantly poten-
tiated the vasodepressor action of Met-enkephalin in
anaesthetized rats. The altered responses to Met-
enkephalin following captopril were not due to
changes either in tissue sensitivity or in experimental
protocol as captopril failed to alter the vasodepressor
responses to the non-specific vasodilator, nitroprus-
side.
Since Met-enkephalin is a substrate for dipeptidyl
dipeptidase (Erdos et al., 1978), captopril may
potentiate the action of circulating Met-enkephalin
by the blockade of this enzyme. Captopril induces
respiratory depression (Oktay et al., 1981) and
analgesia (Ercan et al., 1980) in mice, effects which
could occur by potentiation of endogenous opioids.
The facts that Met-enkephalin is vasodepressor in the
anaesthetized rat (Wei etal., 1980) and that its action
is augmented by captopril suggest that potentiation
of endogenous opioids by captopril may contribute to
its own hypotensive action in anaesthetized SH rats.
However naloxone, at a dose known to antagonize
powerfully the vasodepressor action of Met-
enkephalin (Table 1), failed to alter significantly the
hypertensive action of captopril in anaesthetized SH
rats. Thus, it seems unlikely that potentiation of
endogenous opioids contributes to the hypotensive
action of captopril in these animals.
While captopril is a potent inhibitor of ACE and
Met-enkephalin is a substrate for purified ACE, it is
not known whether the effects of captopril on the
actions of Met-enkephalin seen in this study were due
to the inhibition of ACE and/or some other 'en-
kephalinase'. There is some evidence to suggest that,
in some tissues, there exists an 'enkephalinase' that is
distinct from ACE (Swerts, Perdrisot, Patey, De La
Baume & Schwartz, 1979).
While intravenous Met-enkephalin decreases
blood pressure in the anaesthetized rat (Wei et al.,
1980) and cat (Moore & Dowling, 1980) in the
conscious rat, Met-enkephalin causes an increase in
blood pressure (Simon, Schaz, Ganten, Stock, Schlor
& Ganten, 1978). Thus, potentiation of this opioid by
captopril is unlikely to be involved in the hypotensive
action of captopril in the conscious SH rat. Neverthe-
less similar studies to the present ones are warranted
in conscious animals.
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